Rapamycin Extends Life and Health in C57BL/6 Mice.
Zhang, Yiqiang 1 , 2; Bokov, Alex 1 , 3; Gelfond, John 1 , 3; Soto, Vanessa 1; Ikeno, Yuji 1 , 4 , 5; Hubbard, Gene 1 , 4; Diaz, Vivian 1; Sloane, Lauren 1; Maslin, Keith 2; Treaster, Stephen 2; Rendon, Samantha 1 , 6; van Remmen, Holly 1 , 6; Ward, Walter 1 , 7; Javors, Martin 8; Richardson, Arlan 1 , 7 , 8; Austad, Steven N. 1 , 2 , 6; Fischer, Kathleen 1 , 7
[Article] Journals of Gerontology. Series A, Biological Sciences & Medical Sciences. 69A(2):119-130, February 2014.

(Format: HTML, PDF)

Target of rapamycin inhibition by rapamycin feeding has previously been shown to extend life in genetically heterogeneous mice. To examine whether it similarly affected mouse health, we fed encapsulated rapamycin or a control diet to C57BL/6Nia mice of both sexes starting at 19 months of age. We performed a range of health assessments 6 and 12 months later. Rapamycin feeding significantly reduced mTOR activity in most but not all tissues. It also reduced total and resting metabolic rate during the light (inactive) phase of the light:dark cycle in females only but had no effect on spontaneous activity or metabolism during the dark (active) phase of either sex. Males only had less fragmented sleep when fed rapamycin, whereas stride length and rotarod performance were improved in both sexes. Survival was also improved by this late-life rapamycin feeding, and some pathological lesions were delayed. We found no adverse health consequences associated with rapamycin treatment.

(C) Copyright Oxford University Press 2014.